Ono Pharmaceutical First Quarter 2026 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St · 08/04/2025 00:42

Ono Pharmaceutical (TSE:4528) First Quarter 2026 Results

Key Financial Results

  • Revenue: JP¥127.5b (up 8.4% from 1Q 2025).
  • Net income: JP¥17.7b (down 29% from 1Q 2025).
  • Profit margin: 14% (down from 21% in 1Q 2025). The decrease in margin was driven by higher expenses.
  • EPS: JP¥37.62 (down from JP¥52.79 in 1Q 2025).
earnings-and-revenue-growth
TSE:4528 Earnings and Revenue Growth August 4th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ono Pharmaceutical Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 4.9%. Earnings per share (EPS) missed analyst estimates by 22%.

Looking ahead, revenue is expected to decline by 1.2% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Japan are expected to grow by 3.9%.

Performance of the Japanese Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Ono Pharmaceutical that you should be aware of before investing here.